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Introduction: The objective of asthma management is to control the condition. However,
world-wide surveys reveal that only 5% of asthmatics are well controlled. One reason for this
phenomenon is the fact that patients and doctors consistently over-estimate control. This
study compared patient and doctor assessment of asthma control.
Methods: A random sample of asthmatics was identified by practitioners in South Africa.
Patients completed an Asthma Control Test (ACT) and provided a list of medications currently
being taken. The doctor also provided an assessment of control which was summarised into the
categories - ’not controlled’ and ’controlled’ and listed all medications prescribed.
Results: The mean ACT score was 12.8 where doctors assessed the patients as being ‘not
controlled’ and 20.7 where doctors assessed the patients as being ‘controlled’. Half of the
patients classified themselves as being ‘not controlled’ (ACT score <20, category 1), while
doctors classified only 33% of patients as being ‘not controlled’. Although only 7% of patients
disagreed with the doctor’s classification of ‘not controlled’, 29% disagreed with the doctor’s
assessment of being ‘controlled’. There was a significant difference in ACT score between the
sexes (p < 0.0001). Most therapeutic interventions (with the exception of combination prod-
ucts [ICS þ LABA]) performed poorly with regard to level of control.
Conclusion: This study suggests that asthma still appears to be relatively poorly controlled in
South Africa, although levels of patient control appear to have improved compared to previous
surveys, and confirms that physicians and patients differ in their assessments of asthma
control.
ª 2009 Elsevier Ltd. All rights reserved.27 123545272; fax: þ27
.za (R.J. Green).
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Asthma is a common disease,1 with considerable morbidity
and appreciable mortality. The objective of management is
to control the condition in order to enable the sufferer to
live a life free from symptoms and exacerbations.2,3.
Comparison of doctor and patient assessments of asthma control 357Some of the issues were highlighted in an important study
in Britain in 1992. That study, known as the Lifestyle Study,4
was one of the first large studies to focus on quality of life,
which has now become an important concept in chronic
illnesses. The Lifestyle Study revealed the significant impact
of asthma (even so called ‘‘treated’’ asthma) on the lives of
individuals with the condition. Further asthma-related
quality of life studies and assessments of asthma control have
been numerous.5e9 They reflect a dismal picture of asthma
control around the world with only 5% of asthmatics meeting
the objective of control.10 Reasons for this phenomenon are
many but include the fact that ‘‘patients and doctors
consistently under-estimate severity and control’’10.
The Asthma Insights and Reality in Europe (AIRE) survey5
assessed the level of asthma control, among current asth-
matics in Western Europe, from the patient’s perspective.
Over one-third of children and half of the adults reported
daytime symptoms at least once a week. Furthermore 28%
of children and 30.5% of adults experienced asthma-related
sleep disturbances at least once a week. Patient perception
of asthma control did not match their symptoms severity, as
approximately 50% of those reporting severe persistent
symptoms considered their asthma to be completely or well
controlled. Subsequent and recent studies have revealed
that uncontrolled asthma occurred in between 49%11 and
53%12 of asthmatics in Europe and Canada respectively.
Many studies of this nature have suggested that patients
and their doctors disagree as to the level of control of
asthma with physicians consistently over-estimating
control.13 This has led to strategies relying on patient
assessments of control in guiding therapy adjustments. In
addition, the social cost of asthma and impact on health-
related quality of life will have a direct monetary cost,
adding to the cost of medication and consultations.
Many methods for assessing asthma control have been
suggested (including patient questionnaires, spirometry,
measures of airway hyper-responsiveness and exhaled nitric
oxide), however, for the purposes of this study the ‘gold
standard’ for assessing asthma control used was the ACT
test. This test has been validated for this purpose.14 The
ACT was then compared to clinicians assessment, as would
be done in the real world situation. Doctor assessment in
determining asthma control is an imprecise science and
despite recommendations in asthma guidelines there is
little clear evidence for which questions or combination of
questions actually determine control. There is evidence
that a standardised questionnaire is better than conven-
tional history taking. The GOAL Study authors attempted to
resolve this problem with the Asthma Control Question-
naire.15 In this study the authors used patient’s symptoms
and PEFR over time to assess control and found reasonable
robust cut-points. Also quite interestingly, the positive and
negative predictive values for assessment using the various
cut-points did not change significantly when FEV1 was
omitted. This suggests that spirometry does not add
significantly in determining asthma control.15
This study addresses comparisons between patient and
doctor reported asthma control in South Africa in general,
and with respect to different medical practice types
(private versus public and generalist versus specialist).
Documentation of the relationship between the level of
control and medication being used was also noted.The aim of this study was to compare the relative efficacy
of patient perception obtained by means of a standardised
questionnaire, the ACT, with that of the doctor’s assessment
of asthma control.
Methods
A random sample of asthmatics was identified by medical
practitioners in multiple regions of South Africa. Doctors
participating were selected from the Medical Association
Data Base. Attempts were made to design the study so as to
represent most medical practice types. This was performed
in order to obtain data for patients from public and private
medical facilities, and to include a range of doctor quali-
fications: Urban General Practitioner (GPU), Community
Health Clinic (CHC), Academic Hospital Respiratory Clinic
(RCH) and Specialist Private Pulmonologist (SPP). Each
patient selected was a known asthmatic who was being
seen for a routine follow-up visit. Patients presenting with
acute asthma were excluded.
The study was conducted prospectively and both patients
and doctors were informed that they were taking part in
a clinical study. Patients completed a self-evaluation rating
(ACT) as a measure of their level of asthma control and
provided a list of medications currently being taken. The
doctor also provided a blinded assessment of the same
patient’s level of control using the categories e ‘not well
controlled’, ‘well controlled’ and ‘totally controlled’ and
listed all medications prescribed. The categories ‘well
controlled’ and ‘totally controlled’ were combined for ease
of assessment. These categories will be referred to as ‘not
controlled’ and ‘controlled’. Doctors were not guided in the
way they assessed control. Each practitioner was instructed
to use his usual tools of assessment. These may have
included history taking, examination, spirometry and/or
measures of airway inflammation. The gender of the patient,
their city of residence, the type of practice and the area in
which the site fell, were also recorded.
The ACT score was analysed and in addition was coded
into three sets of categories as described in the original
study14: Category 1 (ACT score 1e19), Category 2 (ACT
score 20e24) and Category 3 (ACT score 25). This facilitated
comparison of the patient self-categorisation with the
doctor’s classification of ‘not well controlled’, ‘well
controlled’ and ‘totally controlled’. For ease of interpre-
tation this paper generally discusses the analysis with
Categories 2 and 3 combined as total asthma control may
reflect too narrow an assessment band. Good (well or
totally controlled) control may be an acceptable level of
asthma control.
Medications listed were classified into standard groups.
Ethics Committee consent was obtained for this study
and patient informed consent was obtained.
Statistical methodology
Association between the patient’s self-assessed ACT score,
and the doctor’s assessment of control (‘not well
controlled’, ‘well controlled’, and ‘totally controlled’) was
tested using the KruskaleWallis analysis of variance test.
Where a significant difference was found (p < 0.05), follow-
Table 1a Number of observations for patient assessed asthma control (ACT) (percentage) compared to doctor assessed level
of control.
Doctor assessed control Mean/Mediana ACT score Total
0e19 20e24 25
Not controlled 12.8/12 391(92.9) 27(6.4) 3(0.7) 421
Well controlled 19.9/20 216(36.3) 357(60) 22(3.7) 595
Total control 22.6/24 34(13.1) 142(54.6) 84(32.3) 260
Total 641 526 89 1276
ACT Z asthma control test.
a Mean/median reflects the mean/median of the ACT scores in the three groups of doctor assessed control (Not controlled, Well
controlled and Total Control).
Table 1b Number of observations for patient assessed asthma control (ACT) (percentage) compared to doctor assessed level
of control, combining well and total control.
Doctor assessed control Mean/Mediana ACT score Total
0e19 20e25
Not controlled 12.8/12 391(92.9) 30(7.1) 421
Controlled (well or total) 20.7/21 250(29.2) 605(70.8) 595
Total 641 635 1276
ACT Z asthma control test.
a Mean/median reflects the mean/median of the ACT scores in the two groups of doctor assessed control (Not controlled and
Controlled).
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adjusted significance level.
Comparison of the measures of control and the grouped
ACT categories was performed using a c2 contingency table
test and Cohen’s Kappa.
The relationship between the patient and doctors
assessment as to the level of control against demographic
variables and medication types was determined using
logistic regression. The demographic variables investigated
were the combination of practice type, city of residence,
and gender. Treatment types investigated were the type of
medication, and, where a combined medication was
prescribed, a test for differences between Salmeterol/
Fluticasone and Formoterol/Budesonide. All interactions
between these variables were investigated.
All analyses were performed using SPSS.16
Results
Comparison of patient recorded asthma control
(ACT) with doctor assessment of control
Significant association existed between the full ACT score
and the doctor’s assessment of control, with themedian ACT
scores increasing over the three categories of doctor
assessments (overall and pair-wise tests, p < 0.0001). The
mean ACT score was 12.8 where doctors assessed the
patients as being ‘not controlled’ and 19.9 where doctors
assessed the patients as being ’well controlled’ (Table 1a).
The mean ACT score was 20.7 when the ACT scores for ‘well
controlled’ and ‘total control’ were added together as‘controlled’ (Table 1b). Half of the patients classified
themselves as being ‘not controlled’ (ACT score <20, cate-
gory 1), while doctors classified only 33% of patients as being
‘not controlled’. Although only 7% of patients disagreed with
the doctor’s classification of ‘not controlled’, 29.2% dis-
agreed with the doctor’s assessment of being ‘controlled’.
Patient (ACT) and doctor assessed control by
practice type, gender and medication use (logistic
regression)
Assessments of asthma control (both by patient (ACT
categories) and doctors) were significantly different
between the practice types (p < 0.0001 for both patient
and doctor). Specialist Private Pulmonologists (SPP)
demonstrated the highest assessments of control. For those
patients at an Academic Hospital Respiratory Clinic (RCH)
the odds of being controlled were 0.303 for patient
assessments and 0.225 for doctor assessments compared to
being controlled if asthma was assessed by a Specialist
Private Pulmonologist. There was also a significant gender
difference (p < 0.0001) for patient assessments but not for
doctor assessments (p Z 0.0618). Median ACT score for
females was 18, and for males 20. Overall 59.4% of males
assessed their asthma control as being ‘controlled’ (20 or
higher) versus only 43.7% of females. The practice type,
gender and medication combinations are shown in Table 2
(patient assessment) and Table 3 (doctor assessment),
which give the number of patients in each category, row
percentage, p value, odds ratio (OR) and 95% confidence
interval for the OR.
Table 2 Comparison of patient assessed level of asthma control over the medication groups as recorded by the doctor, after
adjusting for practice type and sex (numbers of observations, row percentage, significance, odds ratio and the 95% confidence
interval for the odds ratio).
Patient assessed control (ACT category) p OR 95% confidence interval
1 (<20) % 2 þ 3 (20e25) % Total
Practice <0.0001
GPU 69 46.3 80 53.7 149 0.0003 0.545 0.3925 0.7577
CHC 128 74.9 43 25.1 171 0.1808 0.765 0.5169 1.1325
RCH 257 61.0 164 39.0 421 <0.0001 0.303 0.1929 0.4746
SPP 182 35.0 338 65.0 520 e e e e
Sex <0.0001
Male 199 40.8 289 59.2 488 <0.0001 1.665 1.3059 2.1232
Female 437 56.5 336 43.5 773 e e e e
Medication group 0.0001
no ICS 76 55.9 60 44.1 136 0.0002 0.534 0.3841 0.7424
ICS 327 60.1 217 39.9 544 0.0072 0.556 0.3621 0.8527
ICS/LABA separate 89 65.4 47 34.6 136 0.0001 0.389 0.2449 0.6177
Combined ICS/LABA 144 32.4 301 67.6 445 e e e e
Total 636 50.4 625 49.6 1261
Abbreviations: Community Health Clinic (CHC); Academic Hospital Respiratory Clinic (RCH); Urban General Practitioner (GPU); Specialist
Private Pulmonologist (SPP), Inhaled corticosteroid (ICS) (without other drugs except SABA); Long-acting beta-agonist (LABA).
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control, therewas a significant difference between the types
of medication (p < 0.0001, pZ 0.0001). For patient assess-
ment (ACT score) the use of combined ICS/LABA was associ-
ated with significantly better scores than the other 3 groups
(no ICS: pZ 0.0103, ICS: pZ 0.0004, separate: p < 0.0001)
but the scores for the other medication groups did not differ
significantly fromeach other. For doctor assessed control the
reported use of combined ICS/LABA was associated withTable 3 Comparison of doctor assessed level of asthma contro
adjusting for practice type and sex (numbers of observations, row
interval for the odds ratio).
Doctor assessed category
Not controlled Controlled
Practice
GPU 49 32.9 100 67.1
CHC 98 57.3 73 42.7
RCH 169 40.1 252 59.9
SPP 103 19.8 417 80.2
Sex
Male 135 27.7 353 72.3
Female 284 36.7 489 62.3
Medication group
no ICS 50 36.8 86 63.2
ICS 213 39.2 331 60.8
ICS/LABA separate 70 51.5 66 48.5
Combined ICS/LABA 86 19.3 359 80.7
Total 419 33.2 842 66.8
Abbreviations: Community Health Clinic (CHC); Academic Hospital Res
Private Pulmonologist (SPP), Inhaled corticosteroid (ICS); Long-actingsignificantly better assessments than ICS/LABA separate
(pZ<0.0001), but did not differ significantly from the other
two groups (no ICS: p Z 0.1084, ICS: p Z 0.0504). After
controlling for the other factors, the odds, (chance of being
controlled), for those patients on separate ICS/LABA was
0.34 that of being controlled when on combined ICS/LABA.
Alternatively patients were 2.94 times more likely to be
controlled if they were on combined ICS/LABA than on
separate ICS/LABA, according to the doctors classification.l over the medication groups as recorded by the doctor, after
percentage, significance, odds ratio and the 95th confidence
Total p OR 95% confidence interval
<0.0001
149 0.0004 0.526 0.3682 0.7521
171 0.0072 0.558 0.3647 0.8538
421 <0.0001 0.225 0.1452 0.3497
520 e e e e
0.0618
488 0.0618 1.282 0.9878 1.6631
773 e e e e
0.0001
136 0.0573 0.701 0.4856 1.0111
544 0.1192 0.692 0.4351 1.0996
136 <0.0001 0.340 0.2115 0.5454
445 e e e e
1261
piratory Clinic (RCH); Urban General Practitioner (GPU); Specialist
beta-agonist (LABA).
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cantly worse assessment of control than ICS (p Z 0.0005)
and no ICS (p Z 0.0079).
In addition the study could identify the level of agree-
ment between patient and doctor disclosed medication use.
Doctors and patients agreed in 91.9% of cases, but disagreed
in 8.1% of cases. In addition no significant difference was
found between the individual combination agents
(fluticasone þ salmeterol and budesonide þ formoterol) for
the ACT categorisation (p Z 0.8399) or for the doctor
assessed rating (pZ 0.3690).
Discussion
A strength of this study is the relatively large number of
patient and doctor pairs studied. This study suggests that
asthma still appears to be poorly controlled in South Africa.
A significant number of patients (50%) being treated for
asthma identified their control, as measured by the ACT, as
being ‘uncontrolled’. However, this has significantly
improved in contrast to a previous survey, where only 6e8%
of treated asthmatics were considered to be well
controlled.9 This study also reveals that doctors and
patients differ on individual assessments of asthma control.
Doctors classified 39% of patients who assessed their own
control as ACT category 1 (‘not controlled’) to be ‘well and
totally controlled’. This ‘overestimation’ is, however, well
known from previous studies.13 Chapman and colleagues
found very similar disagreements with 59% of patients
indicating uncontrolled asthma while physicians regard only
42% of patients as uncontrolled.13 It should be remembered
that because doctors were not guided in the way they
assessed control, there is a possibility of classification
errors which may influence the results.
Patients on the other hand seldom over-estimated
control, in contrast to their doctor’s assessment of their
control. It is important to repeat this audit to determine
whether the patient’s knowledge of lack of control leads to
a change in medication prescription and management
strategies by doctors to achieve better control. This was
not addressed in this study.
This study highlights some important issues with respect
to level of care for asthmatics as well as therapy selection
to achieve control. Specialist Private Pulmonologists
appeared to perform better than all other groups of doctors
in achieving asthma control in their patients, at least as
indicated by patient ACT results.
The level of control can be expected to vary to a great
extent between primary care and tertiary care.This finding
may however, reflect the specific nature of the population
group treated by this group of doctors. A number of con-
founding variables are possible including medication access
and socioeeconomic factors. This may be especially true of
the group of patients attending Academic Hospital Respi-
ratory Clinics, and Community Health Clinics where medi-
cation access is limited. Increased consultation with
pulmonologists should be made for those patients assessed
as being uncontrolled, by themselves or by their general
practitioner. This phenomenon should be borne in mind in
planning health resources, even in resource-poor settings,
if the goal of asthma management is to achieve control.Secondly the gender discrepancies are interesting. No
previous study has identified major differences between
sexes with respect to asthma control.17,18 In this study
males appeared to be better controlled than females. Our
study was not able to suggest a reason for this.
In general the study suggests that patients generally know
what medication they are using. There is a good correlation
between patient recall of their medication and that noted by
their doctor. This phenomenon may have special relevance
to asthma control as understanding should aid in adherence.
Measures of adherence were not directly measured in this
study but it was noted that the vast majority were
prescribed ICS with which they were familiar. Interestingly
only patients treated with a combination product
(ICS þ LABA) have significantly better asthma control. Lack
of asthma control, as rated by the doctor, for the combi-
nation of ICS/LABA in separate containers is surprising and
needs to be explored. Numerous studies have shown that
combined ICS and LABA achieve better control.19e21 Perhaps
the lack of use of an ICS/LABA combination in the majority of
patient’s is a major factor in their lack of control. All other
therapeutic combinations performed poorly at the level of
asthma control. It should be remembered that this finding,
whilst interesting, should ideally be substantiated by rand-
omised clinical trial as the demographic data and severity of
asthma of the patient population is not adjusted for.
Actual degree of asthma severity has not been elicited in
this study and many overlapping factors may confound
attempts to unravel the phenomenon of lack of control.
However, it shouldbe remembered that this is a large studyof
asthma control with many patient groups and practice types
(from general practitioners to private pulmonologists) being
represented. It is unlikely that only more severe asthmatics
are being studied. Therefore, this study highlights an
important observation about asthma control that should be
noted and digested by all stakeholders in South Africa.
This study suggests one method of determining asthma
control, namely ACT score. However what is still unclear is
how measurement of asthma control is most effectively
performed. Each of the conventional tools for doing this
have both their proponents and detractors and evidence for
and against reliability and validity.11,22 Most previous
studies have shown that clinician assessment of asthma
control, without a specific objective tool perform poorly,
and hence the need to find a more sensitive marker of
control.12 This study does not address the issue of verifying
the asthma control assessments and the relevance of such
assessment in the overall control of patients with asthma.
Conclusion
Asthma remains relatively poorly controlled in South Africa
although the level of control has improved in contrast to
that previously noted. Control is better achieved by Spec-
ilaist Private Pulmonologists in contrast to all other prac-
titioner groups. Patients have a different perception of
their level of control than their doctor. Inexplicably males
appear to be better controlled than females. Those
patients on combination therapy of an ICS and LABA are
best controlled whilst those not on a LABA in addition to an
ICS are less well controlled.
Comparison of doctor and patient assessments of asthma control 361With the recent publication of new asthma guidelines
there is a certain degree of optimism that attempting to
correct the deficiencies of asthma management of the past
may finally be possible. Return to normal life is now the
clear goal of asthma treatment.
This study suggests that physicians and patients may be
capable of assessing asthma control with the various tools
at their disposal but that action on this information to
improve control is needed. This study demonstrates that
there is an opportunity for intervention by doctors to
control asthma better with education remaining a priority.
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